These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 3004187)
1. Effectiveness of converting enzyme inhibition (enalapril) for mild congestive heart failure. Kromer EP; Riegger GA; Liebau G; Kochsiek K Am J Cardiol; 1986 Feb; 57(6):459-62. PubMed ID: 3004187 [TBL] [Abstract][Full Text] [Related]
2. Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure. Pacher R; Stanek B; Globits S; Berger R; Hülsmann M; Wutte M; Frey B; Schuller M; Hartter E; Ogris E Eur Heart J; 1996 Aug; 17(8):1223-32. PubMed ID: 8869864 [TBL] [Abstract][Full Text] [Related]
3. Acute effects of digitalis and enalapril on the neurohormonal profile of chagasic patients with severe congestive heart failure. Khoury AM; Davila DF; Bellabarba G; Donis JH; Torres A; Lemorvan C; Hernandez L; Bishop W Int J Cardiol; 1996 Nov; 57(1):21-9. PubMed ID: 8960939 [TBL] [Abstract][Full Text] [Related]
4. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors. Sigurdsson A Blood Press Suppl; 1995; 1():1-45. PubMed ID: 7599749 [TBL] [Abstract][Full Text] [Related]
5. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. Dunselman PH; Int J Cardiol; 2001 Feb; 77(2-3):131-8; discussion 139-40. PubMed ID: 11182175 [TBL] [Abstract][Full Text] [Related]
6. The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captopril and enalapril. Turini GA; Waeber B; Brunner HR Eur Heart J; 1983 Jan; 4 Suppl A():189-97. PubMed ID: 6301835 [TBL] [Abstract][Full Text] [Related]
7. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study. MacFadyen RJ; Lees KR; Reid JL Br Heart J; 1991 Sep; 66(3):206-11. PubMed ID: 1657084 [TBL] [Abstract][Full Text] [Related]
8. Digoxin, converting-enzyme inhibition (quinapril), and the combination in patients with congestive heart failure functional class II and sinus rhythm. Kromer EP; Elsner D; Riegger GA J Cardiovasc Pharmacol; 1990 Jul; 16(1):9-14. PubMed ID: 1696671 [TBL] [Abstract][Full Text] [Related]
9. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Cleland JG; Dargie HJ; Ball SG; Gillen G; Hodsman GP; Morton JJ; East BW; Robertson I; Ford I; Robertson JI Br Heart J; 1985 Sep; 54(3):305-12. PubMed ID: 2994698 [TBL] [Abstract][Full Text] [Related]
10. Role of angiotensin-converting enzyme inhibitors in congestive heart failure. Galvao M Heart Lung; 1990 Sep; 19(5 Pt 1):505-11. PubMed ID: 2211159 [TBL] [Abstract][Full Text] [Related]
11. [Therapy of dilated cardiomyopathy with digitalis, diuretics and vasodilators]. Liebau G Herz; 1985 Jun; 10(3):138-42. PubMed ID: 2991095 [TBL] [Abstract][Full Text] [Related]
13. Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations. DiCarlo L; Chatterjee K; Parmley WW; Swedberg K; Atherton B; Curran D; Cucci M J Am Coll Cardiol; 1983 Nov; 2(5):865-71. PubMed ID: 6313787 [TBL] [Abstract][Full Text] [Related]
14. Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure. Dickstein K J Cardiovasc Pharmacol; 1987; 9 Suppl 3():S73-81. PubMed ID: 2442558 [TBL] [Abstract][Full Text] [Related]
15. Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure. Fitzpatrick D; Nicholls MG; Ikram H; Espiner EA Br Heart J; 1983 Aug; 50(2):163-9. PubMed ID: 6309203 [TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators. Boden WE; Ziesche S; Carson PE; Conrad CH; Syat D; Cohn JN Am J Cardiol; 1996 May; 77(12):1078-82. PubMed ID: 8644661 [TBL] [Abstract][Full Text] [Related]
17. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Francis GS; Cohn JN; Johnson G; Rector TS; Goldman S; Simon A Circulation; 1993 Jun; 87(6 Suppl):VI40-8. PubMed ID: 8500238 [TBL] [Abstract][Full Text] [Related]
18. Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure. Jorde UP; Vittorio TJ; Dimayuga CA; Homma S; Rizkala A; Le Jemtel TH; Katz SD Am J Cardiol; 2004 Dec; 94(12):1501-5. PubMed ID: 15589004 [TBL] [Abstract][Full Text] [Related]
19. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283 [TBL] [Abstract][Full Text] [Related]